Home / Going-concern warnings / Seres Therapeutics, Inc.
Filed 2025-05-07 路 Form 10-Q 路 Accession 0000950170-25-065173 micro
Price before filing: $8.55 (2025-05-06 close, split/dividend-adjusted)
Market cap at flag: $72.5M (2025-05-07) 路 Latest: $23.7M (2026-10-16)
| Window | MCRB | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -3.7% | +7.2% | -11.0% | 2025-06-06 |
| 90 days | +67.0% | +12.7% | +54.3% | 2025-08-05 |
| 180 days | +78.2% | +23.0% | +55.3% | 2025-11-03 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 5 insiders sold $23K (5 sales)
30 days after: 4 insiders sold $3K (4 sales)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2025-02-18 | DesRosier Thomas Chief Legal Officer and EVP | Sale | 4,300 | $0.81 | $3K | yes | Form 4 |
| 2025-02-18 | Henn Matthew R. See Remarks | Sale | 3,953 | $0.81 | $3K | yes | Form 4 |
| 2025-02-18 | Shaff Eric D. CEO and President, Director | Sale | 12,726 | $0.81 | $10K | yes | Form 4 |
| 2025-02-18 | Young Teresa L. See Remarks | Sale | 3,338 | $0.81 | $3K | yes | Form 4 |
| 2025-02-18 | von Moltke Lisa See Remarks | Sale | 4,416 | $0.81 | $4K | yes | Form 4 |
| 2025-05-07: red flag filed | |||||||
| 2025-05-15 | DesRosier Thomas Chief Legal Officer and EVP | Sale | 79 | $7.28 | $575 | yes | Form 4 |
| 2025-05-16 | Henn Matthew R See Remarks | Sale | 77 | $7.28 | $561 | yes | Form 4 |
| 2025-05-16 | Shaff Eric D. CEO and President, Director | Sale | 220 | $7.28 | $2K | yes | Form 4 |
| 2025-05-16 | Young Teresa L. See Remarks | Sale | 63 | $7.28 | $459 | yes | Form 4 |
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-02-06 to 2025-06-06. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.